Arcadia Biosciences | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 1.302 M

Revenue: As of FY2025 Q3, the actual value is USD 1.302 M, missing the estimate of USD 1.9 M.

EPS: As of FY2025 Q3, the actual value is USD 0.62, beating the estimate of USD -0.54.

EBIT: As of FY2025 Q3, the actual value is USD -1.159 M.

Segment Revenue

• Total Revenues: $1,302 thousand for the three months ended September 30, 2025, compared to $1,537 thousand for the same period in 2024, representing a decrease of 15%.
• Product Revenues: $3,957 thousand for the nine months ended September 30, 2025, compared to $3,829 thousand for the same period in 2024, representing an increase of 3%.

Operational Metrics

• Cost of Revenues: $884 thousand for the three months ended September 30, 2025, compared to $1,032 thousand for the same period in 2024, representing a decrease of 14%.
• Selling, General and Administrative Expenses: $1,570 thousand for the three months ended September 30, 2025, compared to $2,241 thousand for the same period in 2024, representing a decrease of 30%.
• Net Income (Loss) from Continuing Operations: $856 thousand for the three months ended September 30, 2025, compared to a loss of $1,182 thousand for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $3,878 thousand for the nine months ended September 30, 2025, compared to - $7,418 thousand for the same period in 2024.
• Net Cash Provided by Investing Activities: $750 thousand for the nine months ended September 30, 2025, compared to $4,827 thousand for the same period in 2024.

Unique Metrics

• Change in Fair Value of Common Stock Warrant and Option Liabilities: Gain of $560 thousand for the three months ended September 30, 2025, compared to $330 thousand for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Arcadia plans to continue leveraging its history in science-based approaches to develop high-value products and drive innovation in the consumer goods industry, particularly focusing on Zola coconut water products.
• Non-Core Business: The company has exited the GoodWheat brand and does not expect to receive any license or royalty fees related to wheat-based intellectual property rights in the future.
• Priority: The company is closely monitoring the tariff landscape and is in discussions with business partners to explore ways to mitigate the impact of tariffs on the company.